翔宇医疗(688626) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 reached ¥207,118,291.08, representing a year-on-year increase of 52.70%[4] - Net profit attributable to shareholders for Q3 2023 was ¥71,549,371.49, up 35.24% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 131.70% year-on-year, totaling ¥69,941,085.68 for Q3 2023[4] - Total operating revenue for the first three quarters of 2023 reached ¥541,877,308, an increase of 52% compared to ¥356,526,790 in the same period of 2022[23] - Operating profit for the first three quarters of 2023 was ¥188,060,861, up 85.5% from ¥101,257,036 in the first three quarters of 2022[24] - Net profit attributable to shareholders of the parent company for the first three quarters of 2023 was ¥179,162,478, a significant increase from ¥92,910,274 in the same period last year, representing a growth of 92.7%[25] - Basic earnings per share for Q3 2023 were ¥0.46, an increase of 39.39% compared to the same period last year[5] - Basic earnings per share for the first three quarters of 2023 was ¥1.14, compared to ¥0.58 in the same period of 2022, reflecting a 96.6% increase[25] Assets and Liabilities - The total assets of the company at the end of the reporting period were ¥2,664,225,739.61, reflecting a 12.51% increase from the end of the previous year[5] - As of September 30, 2023, the total assets of Henan Xiangyu Medical Equipment Co., Ltd. reached RMB 2,664,225,739.61, an increase from RMB 2,368,078,429.22 at the end of 2022[18] - The company's total equity attributable to shareholders increased by 6.10% year-on-year, reaching ¥2,045,184,385.43[5] - Total assets as of the end of the third quarter of 2023 were ¥2,664,225,739, an increase from ¥2,368,078,429 at the end of the previous year[20] - Total equity attributable to shareholders of the parent company increased to ¥2,045,184,385 from ¥1,927,592,482, marking a growth of 6.1%[20] - The total current liabilities increased to RMB 486,364,363.46 from RMB 351,800,277.93 in the previous year[19] - The total non-current liabilities increased to RMB 119,135,586.90 from RMB 76,419,454.71 in the previous year[19] Research and Development - The company's R&D investment for Q3 2023 was ¥25,473,445.66, accounting for 12.30% of operating revenue, a decrease of 4.32 percentage points year-on-year[5] - Research and development expenses for the first three quarters of 2023 amounted to ¥72,931,856, an increase from ¥66,082,833 in the same period of 2022[24] - The company reported a total of 311 medical device registration certificates and 1,483 patents as of the reporting period, with 18 new registrations and 51 new patents obtained during the quarter[12] - The company achieved a total of 62 new intellectual property rights during the quarter, bringing the cumulative total to 1,771[13] - The company led a project that won the first prize at the 2023 China Rehabilitation Medicine Association Science and Technology Award for the development and promotion of key technologies in swallowing rehabilitation[12] Cash Flow - The cash flow generated from operating activities for the year-to-date period was ¥169,238,341.53, representing an increase of 89.35%[5] - The company reported a net cash inflow from operating activities of ¥647,724,318 for the first three quarters of 2023, compared to ¥520,332,766 in the same period of 2022[27] - Cash flow from operating activities for the first three quarters of 2023 was ¥169,238,341, compared to ¥89,377,803 in the same period of 2022, indicating an increase of 89%[27] - The net cash inflow from investment activities was $1,516,055,387.16, compared to $1,828,229,668.55 in the previous year, reflecting a decrease of approximately 17.1%[29] - The net cash outflow from investment activities was $244,969,918.15, compared to a smaller outflow of $69,604,161.22 in the previous year, indicating a significant increase in cash outflow[29] - The net cash inflow from financing activities was $149,349,919.32, a recovery from a net outflow of $124,338,824.46 in the previous year, showing a positive turnaround[29] - The total cash and cash equivalents at the end of the period amounted to $790,452,828.66, up from $721,936,846.52 at the end of the previous year, representing an increase of approximately 9.5%[29] - The cash inflow from financing activities totaled $278,730,141.17, compared to $46,984,660.00 in the previous year, marking a substantial increase of approximately 493.5%[29] - Cash outflow for financing activities was $129,380,221.85, down from $171,323,484.46 in the previous year, indicating a decrease of about 24.5%[29] - The net increase in cash and cash equivalents for the period was $73,532,412.27, contrasting with a net decrease of $104,339,374.86 in the previous year, indicating a positive shift in cash flow[29]